Clinical trials: Elevated Blood Pressure
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.
- Trial name
- NCT00795639
- Testing
- Sitaxsentan
- Where
- 85 sites in United States, Argentina and 22 more
- Volunteers
- 183 people
- Sponsor
- Pfizer
Hypertension
Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure
This post-marketing surveillance study is designed to supplement under conditions of normal clinical practice data on safety, tolerability and efficacy of Micardis® collected in clinical studies with special emphasis on the…
- Trial name
- NCT02242331
- Testing
- Micardis®
- Volunteers
- 19,805 people
- Sponsor
- Boehringer Ingelheim
Open Angle Glaucoma
Inferonasal MIMS® Procedure: Long-Term Follow-Up Extension Study
A long-term (24 and 30 months) follow-up extension, prospective, non-interventional, open label study for data collection from subjects who underwent prior MIMS® inferonasal surgery, in continuation of the previous clinical…
- Trial name
- NCT06577857
- Testing
- Inferonasal Minimally Invasive Micro Sclerostomy
- Where
- Armenia
- Volunteers
- 44 people
- Sponsor
- Sanoculis Ltd
Hypertension
Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
The study examined the efficacy of LCZ696 in comparison to the ARB olmesartan on Central Aortic Systolic Blood Pressure (CASP) and other measures of central hemodynamics and arterial stiffness in elderly patients with an elevated…
- Trial name
- NCT01692301
- Testing
- LCZ696, Olmesartan, amlodipine
- Where
- 47 sites in United States, Argentina and 10 more
- Volunteers
- 454 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Hypertension,Essential
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
- Trial name
- NCT06205628
- Testing
- ADX-850
- Where
- 3 sites in Australia
- Volunteers
- 28 people
- Sponsor
- ADARx Pharmaceuticals, Inc.
Hypertension
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure
This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil…
- Trial name
- NCT00151775
- Testing
- olmesartan medoxomil
- Where
- 65 sites in United States, Argentina and 9 more
- Volunteers
- 362 people
- Sponsor
- Daiichi Sankyo
Hypertension, Chronic Kidney Disease
Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
The purpose of this study is to assess the long-term safety and tolerability profile of valsartan and valsartan-based treatments in children with hypertension, with or without chronic kidney disease.
- Trial name
- NCT01365481
- Testing
- Valsartan, amlodipine, Hydrochlorothiazide
- Where
- 28 sites in Colombia, Finland and 8 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Open Angle Glaucoma (OAG)
Safety and Performance Study of the CyPass System Applier Model 241
This is a retrospective chart review of cases in which the CyPass Micro-Stent was implanted using the Model 241 Applier. The objective of this study is to characterize and evaluate the safety of the Model 241 Applier when used…
- Trial name
- RePASS (NCT02228577)
- Where
- Germany
- Volunteers
- 172 people
- Sponsor
- Transcend Medical, Inc.
Glaucoma
Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.
This phase IV study aims to assess the safety and the efficacy in intra ocular pressure of Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel) in glaucomatous patients initially treated and stabilised by monotherapy of…
- Trial name
- T1030 (NCT01155219)
- Testing
- Geltim LP 1 mg/g, Xalatan
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Laboratoires Thea
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics
Glaucoma, Open-Angle, Ocular Hypertension
Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
- Trial name
- NCT02250651
- Testing
- Bimatoprost SR, Active Comparator: Timolol 0.5%
- Where
- 113 sites in United States, Argentina and 13 more
- Volunteers
- 528 people
- Sponsor
- Allergan
Hypertension
A Study to Investigate Efficacy and Safety of a TCA108 in Participants ≥18 Years With Uncontrolled Hypertension
The purpose of this study if to evaluate the efficacy and safety of TCA108 on treatment of hypertension.
- Trial name
- TRÍADE-HA (NCT07030101)
- Testing
- TCA108, Bramicar HCT, Micardis Anlo
- Volunteers
- 400 people
- Sponsor
- EMS
Traumatic Brain Injury, Intracranial Hypertension
A Non-invasive Intracranial Pressure (nICP) Monitoring System
Researchers have developed a probe that contains infrared light sources that can illuminate the deep brain tissue of the frontal lobe.
- Trial name
- NCT05632302
- Testing
- nICP
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Crainio Ltda
Hypertension
Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension
Aldazide 25 mg OD will be given to Filipino hypertensive patients, and there will be 2 follow-up visits on week 4 and week 8 to monitor for safety and efficacy as primary and secondary outcomes, respectively.
- Trial name
- NCT01260857
- Testing
- Aldazide
- Sponsor
- Pfizer
Arterial Hypertension
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02483936
- Testing
- Olmesartan medoxomil 40mg + chlorthalidone 12,5mg, Olmesartan medoxomil 40mg + chlorthalidone 25mg, Olmesartan 40mg + Hydrochlorothiazide 12,5mg
- Sponsor
- EMS
Essential Hypertension
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CoCa (NCT00608153)
- Volunteers
- 1,773 people
- Sponsor
- AstraZeneca
Hypertension
National Survey on Hypertension in Cardiologic Private Practice
To evaluate (with sufficient accuracy) the profile(demographic and clinical characteristics, health care management) of hypertensive patients seen in private cardiology consultation by holding account of type of exercise of the…
- Trial name
- Prophyl C (NCT00695175)
- Where
- 408 sites in France
- Volunteers
- 1,800 people
- Sponsor
- AstraZeneca
Essential Hypertension
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential…
- Trial name
- NCT06671392
- Testing
- DWC202405, DWC202405, DWC202314, DWC202405, DWC202314P
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glaucoma, Open-Angle
Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma
This is a prospective, non-significant risk, controlled, randomized, multi-center, masked, feasibility study to evaluate the safety and IOP-lowering effectiveness of negative pressure application (via the Mercury MPD) for…
- Trial name
- NCT04632329
- Testing
- Negative Pressure Treatment via the Mercury Multi-Pressure Dial
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Equinox
Hypertension, Pulmonary
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as…
- Trial name
- RIALTO (NCT02759419)
- Testing
- Adempas (Riociguat, BAY63-2521)
- Where
- 9 sites in France, South Korea
- Volunteers
- 18 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.